insights_auto
Why is IMM down 4.55%?
Dive Deeperchevron_right
IMM:ASX
Immutep Ltd
A$0.021
arrow_downward
-4.55%(-0.0010) 1D
Nov 3, 4:10:15 PM GMT+11 · AUD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMM...
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
35.60M
Avg. vol.
8.48M
Volume
2.42M
52-wk high
A$0.47
52-wk low
A$0.02
EPS
-A$0.05
Shares outstanding
1.47B
No. of employees
19
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
35.60M
Avg. vol.
8.48M
Volume
2.42M
52-wk high
A$0.47
52-wk low
A$0.02
EPS
-A$0.05
Shares outstanding
1.47B
No. of employees
19
News stories
From web sources and news partners
investingLive
·
31 minutes ago
The S&P 500 stays on the back foot amid geopolitical uncertainty as US midterm elections loom. What's next?
The Motley Fool
·
32 minutes ago
The S&P 500's Record Profits Are Hiding a Problem Investors Haven't Seen Before
Yahoo Finance
·
48 minutes ago
iShares Core S&P 500 ETF (IVV) Adds Vylor and Apple on Oct. 30
Barron's
·
1 hour ago
Stocks That Explain Today’s Market
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd